Evidence map›Paper›PMID 32499066›Full record

ArticleVaccine2020

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.

Yap Boum, Aitana Juan-Giner, Matt Hitchings, Aboubacar Soumah, Thomas Strecker, Mariama Sadjo, Hannah Cuthbertson, Peter Hayes, Marie Tchaton, Jean-Paul Jemmy and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Vaccine adjuvants for infectious disease in the clinic.Bioengineering & translational medicine · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 8 countries.

Yap BoumEpicentre, Yaoundé, Cameroon.
Aitana Juan-GinerEpicentre, Paris, France.
Matt HitchingsCenter for Communicable Disease Dynamics and Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Aboubacar SoumahEpicentre, Paris, France.
Thomas StreckerInstitute of Virology, Philipps University, Marburg, Germany.
Mariama SadjoCentre Hospital-Universitaire de Donka, Conakry, Guinea.
Hannah CuthbertsonPublic Health England, National Infection Service, Porton Down, UK.
Peter HayesDivision of Medicine, Department of Infectious Diseases, Imperial College London, UK.
Marie TchatonEpicentre, Paris, France.
Jean-Paul JemmyMédecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
Carolyn ClarckDivision of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
Deborah KingDivision of Medicine, Department of Infectious Diseases, Imperial College London, UK.
Elisabetta Maria FagaMédecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
Stephan BeckerInstitute of Virology, Philipps University, Marburg, Germany.
Bassam HalisPublic Health England, National Infection Service, Porton Down, UK.
Norheim GunnsteinDivision of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
Miles CarrollPublic Health England, National Infection Service, Porton Down, UK.
John-Arne RøttingenDivision of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway; Department of Health and Society, University of Oslo, Norway; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Coalition for Epidemic Preparedness Innovations, Care of Norwegian Institute of Public Health, Oslo, Norway; Research Council of Norway, Oslo, Norway.
Mandy Kader KondéCenter of Excellence for Training, Research On Malaria & Priority Diseases In Guinea, Conakry, Guinea.
Moise DoumbiaWorld Health Organization, Geneva, Switzerland.
Ana-Maria Henao-RestrepoWorld Health Organization, Geneva, Switzerland.
Marie-Paule KienyWorld Health Organization, Geneva, Switzerland.
Mohamed CisseCentre Hospital-Universitaire de Donka, Conakry, Guinea.
Bertrand DraguezMédecins Sans Frontières-Operational Center Belgium, Brussels, Belgium.
Rebecca F GraisEpicentre, Paris, France. Electronic address: Rebecca.grais@epicentre.msf.org.
Médecins Sans Frontières · BEPublic Health England · GBWorld Health Organization · CHDonka Hospital · GNImperial College London · GBNorwegian Institute of Public Health · NOPhilipps University of Marburg · DECenter for Disease Dynamics, Economics & Policy · USEpicentre (South Africa) · ZAThe Research Council of Norway · NO

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundAs part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional information on the immunogenicity of the vaccine.

methodsWe conducted an open-label, non-randomized, single-arm immunogenicity evaluation of one dose of rVSVΔG-ZEBOV-GP among healthy FLWs in Guinea. FLWs who refused vaccination were offered to participate as a control group. We followed participants for 84 days with a subset followed-up for 180 days. The primary endpoint was immune response, as measured by ELISA for ZEBOV-glycoprotein-specific antibodies (ELISA-GP) at 28 days. We also conducted neutralization, whole virion ELISA and enzyme-linked immunospot (ELISPOT) assay for cellular response.

resultsA total of 1172 participants received one dose of vaccine and were followed-up for 84 days, among them 114 participants were followed-up for 180 days. Additionally, 99 participants were included in the control group and followed up for 180 days. Overall, 86.4% (95% CI 84.1-88.4) of vaccinated participants seroresponded at 28 days post-vaccination (ELISA- GP) with 65% of these seroresponding at 14 days post-vaccination. Among those who seroresponded at 28 days, 90.7% (95% CI 82.0-95.4) were still seropositive at 180 days. The proportion of seropositivity in the unvaccinated group was 0.0% (95% CI 0.0-3.8) at 28 days and 5.4% (95% CI 2.1-13.1) at 180 days post-vaccination. We found weak correlation between ELISA-GP and neutralization at baseline but significant pairwise correlation at 28 days post-vaccination. Among samples analysed for cellular response, only 1 (2.2%) exhibited responses towards the Zaire Ebola glycoprotein (Ebola GP ≥ 10) at baseline, 10 (13.5%) at day 28 post-vaccination and 27 (48.2%) at Day 180.

conclusionsWe found one dose of rVSVΔG-ZEBOV-GP to be highly immunogenic at 28- and 180-days post vaccination among frontline workers in Guinea. We also found a cellular response that increased with time.

Indexed as

Ebola VaccinesEbolavirusHemorrhagic Fever, EbolaAfrica, WesternAntibodies, ViralDemocratic Republic of the CongoDisease OutbreaksGuineaHumansImmunity, CellularAntibodies, ViralEbola VaccinesCellular responseEbola vaccineFrontline workersHumoral responseImmunogenicity

Identifiers

PMID32499066
PMCPMC7306162
OpenAlexW3034092089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.